TENAX THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
TENAX THERAPEUTICS, INC. (TENX) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 3.83% for the 9-month period ending 2024-09-30, per its 10-Q filed 2024-11-13.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2024-11-13
- TENAX THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2024-03-31 was 4.12%, a 84.75% increase year-over-year.
- TENAX THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2023-03-31 was 2.23%.
- TENAX THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2016-03-31 was 0.00%, a 100.00% decline year-over-year.
- TENAX THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2015-07-31 was 1.87%, a 16.14% decline year-over-year.
- TENAX THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2023 was 2.23%.
- TENAX THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2017 was 1.83%, a 19.74% decline from fiscal 2016.
- TENAX THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2016 was 2.28%.
- TENAX THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2015 was 2.23%, a 23.89% increase from fiscal 2014.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 8 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month as first filed |
|---|---|---|---|---|---|---|
| 2024-09-30 | 3.83% 10-Q · filed 2024-11-13 | |||||
| 2024-06-30 | 4.12% 10-Q · filed 2024-08-13 | |||||
| 2024-03-31 | 4.12% 10-Q · filed 2024-05-14 | |||||
| 2023-12-31 | 2.23% 10-K · filed 2024-03-28 | |||||
| 2023-09-30 | 2.23% 10-Q · filed 2023-11-13 | |||||
| 2023-06-30 | 2.23% 10-Q · filed 2023-08-14 | |||||
| 2023-03-31 | 2.23% 10-Q · filed 2023-05-15 | |||||
| 2018-09-30 | 2.85% 10-Q · filed 2018-11-14 | |||||
| 2018-06-30 | 2.85% 10-Q · filed 2018-08-14 | |||||
| 2017-12-31 | 1.83% 10-K · filed 2019-04-01 | 2.19% 10-K · filed 2018-04-02 | ||||
| 2017-09-30 | 2.19% 10-Q · filed 2018-11-14 | |||||
| 2017-06-30 | 2.19% 10-Q · filed 2018-08-14 | |||||
| 2016-12-31 | 2.28% 10-K · filed 2018-04-02 | |||||
| 2016-09-30 | 1.60% 10-Q · filed 2017-11-09 | |||||
| 2016-06-30 | 1.60% 10-Q · filed 2017-08-09 | |||||
| 2016-03-31 | 0.00% 10-Q · filed 2016-05-10 | |||||
| 2015-12-31 | 1.99% 10-K · filed 2017-03-16 | |||||
| 2015-10-31 | 1.87% 10-Q · filed 2015-12-10 | |||||
| 2015-09-30 | 1.87% 10-Q · filed 2016-11-09 | |||||
| 2015-07-31 | 1.87% 10-Q · filed 2015-09-09 | |||||
| 2015-06-30 | 1.87% 10-Q · filed 2016-08-09 | |||||
| 2015-04-30 | 2.23% 10-K · filed 2017-03-16 | |||||
| 2015-03-31 | 1.92% 10-Q · filed 2016-05-10 | |||||
| 2015-01-31 | 2.23% 10-Q · filed 2015-03-17 | |||||
| 2014-10-31 | 2.23% 10-Q · filed 2015-12-10 | |||||
| 2014-07-31 | 2.23% 10-Q · filed 2015-09-09 | |||||
| 2014-04-30 | 1.80% 10-K · filed 2017-03-16 | |||||
| 2014-01-31 | 1.12% 10-Q · filed 2015-03-17 | |||||
| 2013-10-31 | 1.11% 10-Q · filed 2014-12-15 | |||||
| 2013-07-31 | 1.11% 10-Q · filed 2014-09-15 | |||||
| 2013-04-30 | 1.29% 10-KT · filed 2016-03-14 | |||||
| 2013-01-31 | 1.29% 10-Q · filed 2014-03-17 | |||||
| 2012-10-31 | 1.29% 10-Q · filed 2013-12-17 | |||||
| 2012-07-31 | 1.31% 10-Q · filed 2013-09-17 | |||||
| 2012-04-30 | 1.79% 10-K · filed 2013-06-26 | |||||
| 2012-01-31 | 2.16% 10-Q · filed 2013-03-18 | |||||
| 2011-10-31 | 2.38% 10-Q · filed 2012-12-14 | |||||
| 2011-07-31 | 2.41% 10-Q · filed 2012-09-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |